Noninvasive early-stage lung cancer detection with high sensitivity, specificity and accuracy bioAffinity Technologies’ flagship product, CyPath® Lung, is a noninvasive test to improve the early detection of lung cancer in patients at high risk for the disease. CyPath® Lung uses advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin, meso-tetra (4-carboxyphenyl) porphyrin (TCPP), that is preferentially taken up by cancer and cancer-related cells. In a clinical study, CyPath® Lung demonstrated 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. CyPath® Lung can be used alone or in combination with other diagnostic tools. CyPath® Lung is marketed as a laboratory developed test by Precision Pathology Laboratory Services, a wholly owned subsidiary of bioAffinity Technologies.
Asian Pacific Society of Respirology
The objectives of the APSR are the advancement and promotion of knowledge of the respiratory system in health and disease. The Society strives to encourage research, improve clinical practice through training, increase awareness of health problems and promote the exchange of knowledge among respirologists in the Asia-Pacific region and beyond.
Ambu
Since 1937, Ambu has been rethinking medical solutions to save lives and improve patient care. Millions of patients and healthcare professionals worldwide depend on the efficiency, safety, and performance of our single-use endoscopy, anesthesia, and patient monitoring solutions. We developed the world’s first sterile, single-use flexible endoscope and, in 2019, secured FDA approval for the aScope 4 RhinoLaryngo. | Ambu is driving innovations in medical technology, serving millions of patients and healthcare professionals worldwide. From the early inventions of the Ambu Bag™ resuscitator and BlueSensor™ electrodes to developing the worlds’ first single-use flexible video bronchoscope, Ambu is building a full suite of products that protect patients by substantially reducing the risk of infection in a cost-effective way. Headquartered in Denmark, Ambu employs approximately 4,500 in Europe, North America and the Asia Pacific. Visit www.ambuusa.com. | Since 1937, Ambu has been rethinking solutions to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our emergency care solutions. From the original Ambu self-inflating resuscitation bag to the first fully integrated wireless training manikin, Ambu works closely with first responders and educators to develop tools that take the latest training requirements and techniques into account.
AgeTech Collaborative from AARP
The AgeTech Collaborative™ from AARP® brings together a one-of-a-kind ecosystem of key stakeholders, united in their mission to improve people’s lives as they age. Backed by decades of AARP’s exclusive longevity insights, subject-matter experts, and hands-on guidance, we are driving innovation at the nexus of longevity and technology. | Backed by decades of AARP’s exclusive longevity insights, subject-matter experts, and hands-on guidance, the AgeTech Collaborative is on a mission to drive innovation at the nexus of longevity and technology. We work to accelerate impact in Agetech in three key areas: discovery, support, and inclusive growth. Through our one-of-a-kind accelerator program, we bring together an exclusive ecosystem of startups, enterprises, investors, and testbeds dedicated to making aging easier for everyone.
Accessia Health
Accessia Health, a nonprofit patient assistance organization, supports individuals living with rare or chronic health conditions. Through our 80+ disease programs we offer case management, financial assistance, education, and other related services. Our holistic, inclusive, and outcomes-focused approach addresses unmet needs and improves access to health care.
4DMedical
4DMedical is a global leader in innovative respiratory and cardiopulmonary imaging software. Our SaaS solutions deliver non-invasive, regional, and lobar quantitative lung function analysis—giving pulmonologists and clinicians the power to act sooner and with objective data for patients with unexplained dyspnea, asthma, COPD, and other lung diseases. We also support early intervention with low-dose lung health screenings and physician-customized smoking cessation tools to help prevent disease progression. 4DMedical’s CT:VQ™ is the world’s first and only non-contrast post-processing technology that transforms routine chest CT scans into detailed, quantitative maps of lung ventilation (V) and perfusion (Q), all without injected contrast or radioisotopes. CT:VQ™ seamlessly fits into your existing workflow, delivering results directly for rapid interpretation—all from the CT you already order. You can act sooner with objective perfusion data—from the CT you already order. Enhance patient care with actionable functional data from every chest CT—accelerating your path from suspicion to confident clinical decision. | 4DMedical is a global leader in innovative respiratory and cardiopulmonary imaging software. Using advanced, non-invasive CT imaging technology, our SaaS offerings provide non-invasive, regional and lobar quantitative lung function analysis for unparalleled insights into cardiopulmonary health. With a single CT lung scan, 4DMedical provides automated, quantitative analysis that equips radiologists with detailed insights to support ordering physicians in delivering optimal patient care. Now available: CT:VQ™ is the world’s first and only non-contrast post-processing technology that transforms routine chest CT scans into quantitative, lobar ventilation (V) and perfusion (Q) maps—without contrast media, inhaled agents, or added scan time. Results are automatically delivered to PACS, ready for radiologist interpretation alongside the source CT images. For Radiologists: – One modality, one department: Complete pulmonary imaging with no new hardware or workflow steps – Add objective, functional metrics to every routine CT – Improve reporting consistency and inter-reader reproducibility – Automated, quantitative reporting and seamless PACS integration – Peer-reviewed, proven correlation with spirometry and radiologist-based metrics – Enhance your CT utility—structure and function, together in a single exam With 4DMedical, radiologists can deliver both structural and functional lung, and cardiac assessment from standard CT, enhancing diagnostic confidence, improving report value, and streamlining workflow efficiency.